3) Limitations in clinical translation and biomarker development: A major translational barrier is the absence of ADPKD-specific, non-invasive ferroptosis biomarkers with clinical utility
For some, particularly those with permanent malabsorption issues, injections are a regular, lifelong requirement, typically lasting between two to three months per dose
10.1093/clinchem/44.3.487 192 FishW
Mt n prettyskin ( glutathione 350-mu Hng) 40.000 Gi gc l: 40.000.25.000Gi hin ti l: 25.000
doi:10.1530/eje.1.02128 [5] Arduc A, Aycicek Dogan B, Bilmez S Imga Nasirouglu N, Tuna MM, Isik S, Berker D, Guler S